Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 20, 2020 - Issue 1
Submit an article Journal homepage
18,946
Views
35
CrossRef citations to date
0
Altmetric
Perspective

Fixed dose drug combinations – are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries

Brian Godmana Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK;b Division of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa;c Division of Clinical Pharmacology, Karolinska Institute, Karolinska University Hospital Huddinge, Stockholm, Sweden;d School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, MalaysiaCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0001-6539-6972View further author information
ORCID Icon,
Holly McCabee Department of Management Science, Strathclyde Business School, University of Strathclyde, Glasgow, UKView further author information
,
Trudy D Leongf Essential Drugs Programme, Affordable Medicines Directorate, South African National Department of Health, Pretoria, South AfricaORCID Iconhttps://orcid.org/0000-0003-2687-7751View further author information
ORCID Icon,
Debjani Muellerg Department of Public Health Medicine, Steve Biko Academic Hospital and University of Pretoria, Pretoria, South Africa;h Charlotte Maxeke Medical Research Cluster, Johannesburg, South AfricaView further author information
,
Antony P. Martini Health Economics Centre, University of Liverpool Management School, Liverpool, UK;j HCD Economics, The Innovation Centre, Daresbury, UKORCID Iconhttps://orcid.org/0000-0003-4383-6038View further author information
ORCID Icon,
Iris Hoxhak Department of Pharmacy, Faculty of Medicine, University of Medicine Tirana, Tirana, AlbaniaView further author information
,
Julius C. Mwital Department of Internal Medicine, Faculty of Medicine, University of Botswana, Gaborone, BotswanaORCID Iconhttps://orcid.org/0000-0002-5947-3684View further author information
ORCID Icon,
Godfrey Mutashambara Rwegereram Faculty of Medicine, Department of Internal Medicine, University of Botswana and Department of Medicine, Princess Marina Hospital, Gaborone, BotswanaORCID Iconhttps://orcid.org/0000-0002-5896-6065View further author information
ORCID Icon,
Amos Masselen Department of Biomedical Sciences, Faculty of Medicine, University of Botswana, Gaborone, BotswanaView further author information
,
Juliana de Oliveira Costao SUS Collaborating Centre for Technology Assessment & Excellence in Health, Universidade Federal De Minas Gerais, Belo Horizonte, Brazil;p Programa De Pós-Graduação Em Saúde Pública, Faculdade De Medicina, Universidade Federal De Minas Gerais, Belo Horizonte, Minas Gerais, Brazil;q Centre for Big Data Research in Health, UNSW Sydney, Sydney, NSW, AustraliaORCID Iconhttps://orcid.org/0000-0002-8355-023XView further author information
ORCID Icon,
Renata Cristina Rezende Macedo do Nascimentoa Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK;r Departament of Pharmacy, School of Pharmacy, Federal University of Ouro Preto (UFOP), Ouro Preto, BrazilORCID Iconhttps://orcid.org/0000-0001-7756-2157View further author information
ORCID Icon,
Livia Lovato Pires de Lemoso SUS Collaborating Centre for Technology Assessment & Excellence in Health, Universidade Federal De Minas Gerais, Belo Horizonte, Brazil;p Programa De Pós-Graduação Em Saúde Pública, Faculdade De Medicina, Universidade Federal De Minas Gerais, Belo Horizonte, Minas Gerais, BrazilORCID Iconhttps://orcid.org/0000-0002-8921-515XView further author information
ORCID Icon,
Konstantin Tachkovs Faculty of Pharmacy, Department of Social Pharmacy and Pharmacoeconomics, Medical University of Sofia, Sofia, BulgariaORCID Iconhttps://orcid.org/0000-0002-3961-7556View further author information
ORCID Icon,
Petya Milushewas Faculty of Pharmacy, Department of Social Pharmacy and Pharmacoeconomics, Medical University of Sofia, Sofia, BulgariaView further author information
,
Okwen Patrickt Effective Basic Services (Ebase) Africa, Bamenda, Cameroon, Africa;u Adelaide University, Adelaide, AustraliaView further author information
,
Loveline Lum Nibat Effective Basic Services (Ebase) Africa, Bamenda, Cameroon, Africa;v Department of Public Health, University of Bamenda, Bambili, CameroonView further author information
,
Ott Laiusw State Agency of Medicines, Tartu, EstoniaView further author information
,
Israel Sefahx Department of Pharmacy, Keta Municipal Hospital, Ghana Health Service, GhanaORCID Iconhttps://orcid.org/0000-0001-6963-0519View further author information
ORCID Icon,
Suhaj Abdulsalimy Department of Pharmacy Practice, Unaizah College of Pharmacy, Qassim University, Qassim, Saudi ArabiaORCID Iconhttps://orcid.org/0000-0002-6450-9848View further author information
ORCID Icon,
Fatemeh Soleymaniz Pharmaceutical Management & Economic Research Center, Tehran University of Medical Sciences, Tehran, Iran;aa Department of Pharmacoeconomics and Pharmaceutical Management, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IranORCID Iconhttps://orcid.org/0000-0002-6920-8796View further author information
ORCID Icon,
Anastasia N Guantaibb Department of Pharmacology and Pharmacognosy, School of Pharmacy, University of Nairobi, Nairobi, KenyaView further author information
,
Loice Achiengcc Department of Clinical Medicine and Therapeutics, School of Medicine, University of Nairobi, Nairobi, KenyaORCID Iconhttps://orcid.org/0000-0003-4632-8792View further author information
ORCID Icon,
Margaret Olukabb Department of Pharmacology and Pharmacognosy, School of Pharmacy, University of Nairobi, Nairobi, KenyaView further author information
,
Arianit Jakupidd UBT– Higher Education Institution, Prishtina, KosovoView further author information
,
Konstantīns Logvissee Institute of Public Health & Department of Dosage Form Technology, Faculty of Pharmacy, Riga Stradins University, LatviaView further author information
,
Mohamed Azmi Hassalid School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, MalaysiaORCID Iconhttps://orcid.org/0000-0001-9575-403XView further author information
ORCID Icon,
Dan Kibuuleff Department of Pharmacy Practice and Policy, Faculty of Health Sciences, University of Namibia, Windhoek, NamibiaORCID Iconhttps://orcid.org/0000-0002-6908-2177View further author information
ORCID Icon,
Francis Kalemeeraff Department of Pharmacy Practice and Policy, Faculty of Health Sciences, University of Namibia, Windhoek, NamibiaORCID Iconhttps://orcid.org/0000-0002-4320-5087View further author information
ORCID Icon,
Mwangana Mubitaff Department of Pharmacy Practice and Policy, Faculty of Health Sciences, University of Namibia, Windhoek, NamibiaView further author information
,
Joseph Fadaregg Department of Pharmacology and Therapeutics, Ekiti State University, Ado-Ekiti, Nigeria;hh Department of Medicine, Ekiti State University Teaching Hospital, Ado-Ekiti, NigeriaORCID Iconhttps://orcid.org/0000-0002-5641-1402View further author information
ORCID Icon,
Olayinka O. Ogunleyeii Department of Pharmacology, Therapeutics and Toxicology, Lagos State University College of Medicine, Ikeja, Lagos, Nigeria;jj Department of Medicine, Lagos State University Teaching Hospital, Ikeja, Lagos, NigeriaORCID Iconhttps://orcid.org/0000-0002-8921-1909View further author information
ORCID Icon,
Zikria Saleemkk Faculty of Pharmacy, The University of Lahore, Lahore, PakistanORCID Iconhttps://orcid.org/0000-0003-3202-6347View further author information
ORCID Icon,
Shazhad Hussainll National Institute of Health, Islamabad, PakistanView further author information
,
Tomasz Bochenekmm Department of Nutrition and Drug Research, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, PolandORCID Iconhttps://orcid.org/0000-0001-9915-7267View further author information
ORCID Icon,
Ileana Mardarenn Faculty of Medicine, Public Health and Management Department, “Carol Davila” University of Medicine and Pharmacy Bucharest, Bucharest, RomaniaORCID Iconhttps://orcid.org/0000-0002-4725-9808View further author information
ORCID Icon,
Alian A. Alrasheedyoo Unaizah College of Pharmacy, Qassim University, Qassim, Saudi ArabiaORCID Iconhttps://orcid.org/0000-0003-3617-7425View further author information
ORCID Icon,
Jurij Furstpp Health Insurance Institute, Ljubljana, SloveniaView further author information
,
Dominik Tomekqq Faculty of Medicine, Slovak Medical University in Bratislava, Bratislava, SlovakiaView further author information
,
Vanda Markovic-Pekovicrr Department of Social Pharmacy, Faculty of Medicine, University of Banja Luka, Republic of Srpska, Bosnia and HerzegovinaORCID Iconhttps://orcid.org/0000-0001-8963-5720View further author information
ORCID Icon,
Enos M. Rampambab Division of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa;ss Department of Pharmacy, Tshilidzini Hospital, Limpopo Department of Health, Limpopo Province, South AfricaORCID Iconhttps://orcid.org/0000-0002-3492-9104View further author information
ORCID Icon,
Abubakr Alfadloo Unaizah College of Pharmacy, Qassim University, Qassim, Saudi Arabia;tt Medicines and Poison Board, Federal Ministry of Health, Khartoum, SudanORCID Iconhttps://orcid.org/0000-0002-3014-1408View further author information
ORCID Icon,
Adefolarin A Amuuu Eswatini Medical Christian University, Mbabane, Kingdom of EswatiniView further author information
,
Zinhle Matsebulavv Raleigh Fitkin Memorial Hospital, Manzini, Kingdom of EswatiniView further author information
,
Thuy Nguyen Thi Phuongww Pharmaceutical Administration & PharmacoEconomics, Hanoi University of Pharmacy, VietnamORCID Iconhttps://orcid.org/0000-0001-7939-5276View further author information
ORCID Icon,
Binh Nguyen Thanhww Pharmaceutical Administration & PharmacoEconomics, Hanoi University of Pharmacy, VietnamView further author information
,
Aubrey Chichonyi Kalungiaxx Department of Pharmacy, University of Zambia, Lusaka, ZambiaORCID Iconhttps://orcid.org/0000-0003-2554-1236View further author information
ORCID Icon,
Trust Zaranyikayy Department Of Medicine, University of Zimbabwe College of Health Sciences, Harare, ZimbabweORCID Iconhttps://orcid.org/0000-0003-4363-7709View further author information
ORCID Icon,
Nyasha Masukazz Independent Health Systems Consultant, Harare, ZimbabweORCID Iconhttps://orcid.org/0000-0003-4653-8626View further author information
ORCID Icon,
Ioana D. Olaruaaa Clinical Research Department, London School of Hygiene and Tropical Medicine, London, UK;bbb Biomedical Research and Training Institute, Harare, ZimbabweORCID Iconhttps://orcid.org/0000-0003-3392-9257View further author information
ORCID Icon,
Janney Waleccc Independent Consumer Advocate, Brunswick, Victoria, AustraliaView further author information
,
Ruaraidh Hillddd Liverpool Reviews and Implementation Group, Whelan Building, Liverpool University, Liverpool, UKORCID Iconhttps://orcid.org/0000-0002-2801-0505View further author information
ORCID Icon,
Amanj Kurdia Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK;eee Department of Pharmacology, College of Pharmacy, Hawler Medical University, Erbil, IraqORCID Iconhttps://orcid.org/0000-0001-5036-1988View further author information
ORCID Icon,
Angela Timoneya Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK;fff NHS Lothian Director of Pharmacy, NHS Lothian, Edinburgh, UKView further author information
,
Stephen Campbellggg Centre for Primary Care, Division of Population Health, Health Services Research and Primary Care, University of Manchester, Manchester, UK;hhh NIHR Greater Manchester Patient Safety Translational Research Centre, School of Health Sciences, University of Manchester, Manchester, UKORCID Iconhttps://orcid.org/0000-0002-2328-4136View further author information
ORCID Icon &
Johanna C. Meyerb Division of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South AfricaORCID Iconhttps://orcid.org/0000-0003-0462-5713View further author information
ORCID Icon show all
Pages 1-26 | Received 17 Jan 2020, Accepted 21 Feb 2020, Published online: 01 Apr 2020

References

  • Gautam CS, Saha L. Fixed dose drug combinations (FDCs): rational or irrational: a view point. Br J Clin Pharmacol. 2008;65(5):795–796.
  • Sreedhar D, Subramanian G, Udupa N. Combination drugs: are they rational? Curr Sci. 2006;91:406.
  • EMA. Guideline on clinical development of fixed combination medicinal products. 2017 [cited 2019 Oct 10]. Available from https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-development-fixed-combination-medicinal-products-revision-2_en.pdf
  • Auwal F, Dahiru MN, Abdu-Aguye SN. Availability and rationality of fixed dose combinations available in Kaduna, Nigeria. Pharm Pract (Granada). 2019;17(2):1470.
  • Sawicki-Wrzask D, Thomsen M, Bjerrum OJ. An analysis of the fixed-dose combinations authorized by the European Union, 2009–2014: a focus on benefit-risk and clinical development conditions. Ther Innov Regul Sci. 2015;49(4):553–559.
  • Duconge J, Ruano G. Fixed-dose combination products and unintended drug interactions: urgent need for pharmacogenetic evaluation. Pharmacogenomics. 2015;16(15):1685–1688.
  • Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713–719.
  • Blaszczyk B, Miziak B, Czuczwar P, et al. A viewpoint on rational and irrational fixed-drug combinations. Expert Rev Clin Pharmacol. 2018;11(8):761–771.
  • Fortin A, Verbeeck RK, Jansen FH. Comparative oral bioavailability of non-fixed and fixed combinations of artesunate and amodiaquine in healthy Indian male volunteers. Eur J Clin Pharmacol. 2011;67(3):267–275.
  • Dubey R. Bioequivalence challenges in development of fixed-dose combination products: looking beyond reformulation. Expert Opin Drug Deliv. 2012;9(3):325–332.
  • McGettigan P, Roderick P, Kadam A, et al. Threats to global antimicrobial resistance control: centrally approved and unapproved antibiotic formulations sold in India. Br J Clin Pharmacol. 2019;85(1):59–70.
  • ReAct. Why are fixed dose combinations of antibiotics generally not a good idea? 2018 [cited 2019 Oct 15]. Available from: https://www.reactgroup.org/news-and-views/news-and-opinions/year-2018/why-are-fixed-dose-combinations-of-antibiotics-generally-not-a-good-idea/
  • Menditto E, Orlando V, De Rosa G, et al. Patient centric pharmaceutical drug product design-the impact on medication adherence. Pharmaceutics. 2020;12(1):E44.
  • Gupta YK, Ramachandran SS. Fixed dose drug combinations: issues and challenges in India. Indian J Pharmacol. 2016;48(4):347–349.
  • Bjerrum OJ, Gautam Y, Honore´ PH, et al. Drug-drug combinations revisited. Eur J Hosp Pharm. 2014;21:8–12.
  • Kalaba M, Godman B, Vuksanovic A, et al. Possible ways to enhance renin-angiotensin prescribing efficiency: republic of Serbia as a case history? J Comp Eff Res. 2012;1(6):539–549.
  • Clarke PM, Avery AM. Perspectives - Evaluating the costs and benefits of using combination therapies. MJA. 2014;200(9):1–3.
  • Iftikha S, Sarwar MR. Potential disadvantages associated with treatment of active tuberculosis using fixed-dose combination: a review of literature. J Basic Clin Pharm. 2017;8:S131–136.
  • Desai D, Wang J, Wen H, et al. Formulation design, challenges, and development considerations for fixed dose combination (FDC) of oral solid dosage forms. Pharm Dev Technol. 2013;18(6):1265–1276.
  • Poulter NR, Dolan E, Gupta AK, et al. Efficacy and safety of incremental dosing of a new single-pill formulation of perindopril and amlodipine in the management of hypertension. Am J Cardiovasc Drugs. 2019;19(3):313–323.
  • Abhyankar D, Shedage A, Gole M, et al. Pharmacokinetics of fixed-dose combination of tenofovir disoproxil fumarate, lamivudine, and efavirenz: results of a randomized, crossover, bioequivalence study. Int J STD AIDS. 2017;28(5):491–498.
  • Hanning SM, Lopez FL, Wong ICK, et al. Patient centric formulations for paediatrics and geriatrics: similarities and differences. Int J Pharm. 2016;512(2):355–359.
  • McCabe H, Godman B, Kurdi A, et al. Prescribing trends of inhaler treatments for asthma and chronic obstructive pulmonary disease within a resource-constrained environment in the Scottish national health service: findings and implications. Expert Rev Respir Med. 2019;13(7):679–689.
  • Podolsky SH, Greene JA. Combination drugs–hype, harm, and hope. N Engl J Med. 2011;365(6):488–491.
  • Wertheimer AI. The economics of polypharmacology: fixed dose combinations and drug cocktails. Curr Med Chem. 2013;20(13):1635–1638.
  • Poudel A, Mohamed Ibrahim MI, Mishra P, et al. Assessment of the availability and rationality of unregistered fixed dose drug combinations in Nepal: a multicenter cross-sectional study. Glob Health Res Policy. 2017;2:14.
  • Evans V, Roderick P, Pollock AM. Adequacy of clinical trial evidence of metformin fixed-dose combinations for the treatment of type 2 diabetes mellitus in India. BMJ Glob Health. 2018;3(2):e000263.
  • McGettigan P, Roderick P, Mahajan R, et al. Use of fixed dose combination (FDC) drugs in India: central regulatory approval and sales of FDCs containing non-steroidal anti-inflammatory drugs (NSAIDs), metformin, or psychotropic drugs. PLoS Med. 2015;12(5):e1001826; discussion e.
  • Miranda MRH, Dubey A, GS R, et al. Fixed-dose combinations banned in India: is it the right decision? An eye-opening review. Expert Opin Drug Saf. 2019;18(10):977–985.
  • Hussain S, Malik F, Mehmood W, et al. Assessment of bioavailability of rifampicin as a component of anti-tubercular fixed dose combination drugs marketed in Pakistan. J Bioequivalence Bioavailability. 2010;2:067071.
  • Khan B, Godman B, Babar A, et al. Assessment of active pharmaceutical ingredients in the registration procedures in Pakistan: implications for the future. GaBI J. 2016;5(4):156–163.
  • Cohen CJ, Meyers JL, Davis KL. Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV. BMJ Open. 2013;3:8.
  • Colombo GL, Castagna A, Di Matteo S, et al. Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting. Ther Clin Risk Manag. 2014;10:9–15.
  • Dubrocq G, Rakhmanina N. The pharmacokinetics, pharmacodynamics, and clinical role of fixed dose combination of tenofovir disoproxil fumarate, lamivudine and reduced dose efavirenz (TLE-400) in treating HIV-1 infection. Expert Opin Drug Metab Toxicol. 2018;14(8):773–779.
  • Schellack N, Malan L. An overview of fixed-dose combinations of antihypertensive drugs in South Africa. South Afr Fam Pract. 2014;56(4):206–211.
  • Gupta R, Malhotra A, Malhotra P. Assessment of rational use of fixed dose combinations in hypertension in a tertiary care teaching hospital in north India. Int J Adv Med. 2018;5:1263–1267.
  • Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399–407.
  • Singh K, Crossan C, Laba TL, et al. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: within-trial cost-effectiveness analysis of the UMPIRE trial. Int J Cardiol. 2018;262:71–78.
  • Vrijens B, Antoniou S, Burnier M, et al. Current situation of medication adherence in hypertension. Front Pharmacol. 2017;8:100.
  • Lin JK, Moran AE, Bibbins-Domingo K, et al. Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa: a modelling study. Lancet Glob Health. 2019;7(10):e1346–e58.
  • Gonzalez-Gomez S, Melendez-Gomez MA, Lopez-Jaramillo P. Fixed-dose combination therapy to improve hypertension treatment and control in Latin America. Arch Cardiol Mex. 2018;88(2):129–135.
  • Becerra V, Gracia A, Desai K, et al. Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK. BMJ Open. 2015;5(5):e007111.
  • Deshmukh KBS, Qian J, Garza KB, et al. Health care costs associated with addition, titration, and switching antihypertensive medications after first-line treatment: results from a commercially insured sample. J Manag Care Spec Pharm. 2017;23(6):691–699.
  • Ramjan R, Calmy A, Vitoria M, et al. Systematic review and meta-analysis: patient and programme impact of fixed-dose combination antiretroviral therapy. Trop Med Int Health. 2014;19(5):501–513.
  • Hilleman DE. Adherence and health care costs with single-pill fixed-dose combinations in hypertension management. J Managed Care Pharm. 2014;20(1):93–100.
  • CADTH Common Drug. Reviews. Clinical review report: empagliflozin and metformin fixed-dose combination (Synjardy). Ottawa (ON): Canadian Agency for Drugs and Technologies in Health Copyright (c) 2017 Canadian Agency for Drugs and Technologies in Health. 2017.
  • Connor J, Rafter N, Rodgers A. Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. Bull World Health Organ. 2004;82(12):935–939.
  • van Galen KA, Nellen JF, Nieuwkerk PT. The effect on treatment adherence of administering drugs as fixed-dose combinations versus as separate pills: systematic review and meta-analysis. AIDS Res Treat. 2014;2014:967073.
  • Llibre JM, de Lazzari E, Molina JM, et al. Cost-effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different components. Enferm Infecc Microbiol Clin. 2018;36(1):16–20.
  • Cazzola M, Matera MG. Fixed-dose combination inhalers. Handb Exp Pharmacol. 2017;237:117–129.
  • Desmeules J, Rollason V, Piguet V, et al. Clinical pharmacology and rationale of analgesic combinations. Eur J Anaesthesiol Suppl. 2003;28:7–11.
  • Raffa RB. Pharmacology of oral combination analgesics: rational therapy for pain. J Clin Pharm Ther. 2001;26(4):257–264.
  • Raffa RB, Tallarida RJ, Taylor R Jr., et al. Fixed-dose combinations for emerging treatment of pain. Expert Opin Pharmacother. 2012;13(9):1261–1270.
  • O’Brien J, Pergolizzi J Jr, van de Laar M, et al. Fixed-dose combinations at the front line of multimodal pain management: perspective of the nurse-prescriber. Nurs Res Rev. 2013;3:9–22.
  • Ong CK, Seymour RA, Lirk P, et al. Combining paracetamol (acetaminophen) with nonsteroidal antiinflammatory drugs: a qualitative systematic review of analgesic efficacy for acute postoperative pain. Anesth Analg. 2010;110(4):1170–1179.
  • Daniels SE, Atkinson HC, Stanescu I, et al. Analgesic efficacy of an acetaminophen/ibuprofen fixed-dose combination in moderate to severe postoperative dental pain: a randomized, double-blind, parallel-group, placebo-controlled trial. Clin Ther. 2018;40(10):1765–76.e5.
  • Kawalec P, Holko P, Gawin M, et al. Effectiveness of fixed-dose combination therapy in hypertension: systematic review and meta-analysis. Arch Med Sci. 2018;14(5):1125–1136.
  • Walensky RP, Sax PE, Nakamura YM, et al. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med. 2013;158(2):84–92.
  • Kannan S, Mahadevan S, Ramakrishnan A. Fixed dose combinations for type 2 diabetes. Lancet Diabetes Endocrinol. 2015;3(6):408.
  • WHO. Fixed‐dose combinations for HIV/AIDS, tuberculosis, and malaria. 2003 [cited 2019 Oct 10]. Available from: https://apps.who.int/medicinedocs/pdf/s6172e/s6172e.pdf.
  • Purdy M, Robinson M, Wei K, et al. The economic case for combating malaria. Am J Trop Med Hyg. 2013;89(5):819–823.
  • Mwita SJM, Marwa K, Hamasaki K, et al. Medicines dispensers’ knowledge on the implementation of an artemisinin-based combination therapy policy for the treatment of uncomplicated malaria in Tanzania. J Pharm Health Serv Res. 2017;8:227–233.
  • Kibuule D, Rennie TW, Ruswa N, et al. Effectiveness of community-based DOTS strategy on tuberculosis treatment success rates in Namibia. Int J Tuberc Lung Dis. 2019;23(4):441–449.
  • Wang H, Wolock TM, Carter A, et al. Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the global burden of disease study 2015. Lancet HIV. 2016;3(8):e361–87.
  • Rankgoane-Pono G, Tshikuka JG, Magafu MGMD, et al. Incidence of diabetes mellitus-related comorbidities among patients attending two major HIV clinics in Botswana: a 12-year retrospective cohort study. BMC Res Notes. 2018;11(1):90.
  • Haacker M, Barnighausen T, Atun R. HIV and the growing health burden from noncommunicable diseases in Botswana: modelling study. J Glob Health. 2019;9(1):010428.
  • Njuguna B, Kiplagat J, Bloomfield GS, et al. Prevalence, risk factors, and pathophysiology of dysglycemia among people living with HIV in Sub-Saharan Africa. J Diabetes Res. 2018;2018:6916497.
  • Mutemwa M, Peer N, de Villiers A, et al. Prevalence, detection, treatment, and control of hypertension in human immunodeficiency virus (HIV)-infected patients attending HIV clinics in the Western Cape Province, South Africa. Medicine (Baltimore). 2018;97(35):e12121.
  • Berkowitz N, Okorie A, Goliath R, et al. The prevalence and determinants of active tuberculosis among diabetes patients in Cape Town, South Africa, a high HIV/TB burden setting. Diabetes Res Clin Pract. 2018;138:16–25.
  • Gallardo CR, Rigau Comas D, Valderrama Rodriguez A, et al. Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis. Cochrane Database Syst Rev. 2016;(5):Cd009913.
  • Caplan MR, Daar ES, Corado KC. Next generation fixed dose combination pharmacotherapies for treating HIV. Expert Opin Pharmacother. 2018;19(6):589–596.
  • Homar F, Lozano V, Martínez-Gómez J, et al. Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCs) were stopped, versus continuation with FDCs. Health Econ Rev. 2012;2(1):16.
  • WHO Global tuberculosis report (Full) 2019 [cited 2019 Oct 12]. Available from: https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf?ua=1
  • Mahipala P, Dorji G, Tisocki K, et al. A critical review of addressing cardiovascular and other non-communicable diseases through a primary health care approach in the South-East Asia Region. Cardiovasc Diagn Ther. 2019;9(2):150–157.
  • International Diabetes Federation. IDF Atlas Ninth Edition. 2019. Available from: https://diabetesatlas.org/upload/resources/material/20200106_152211_IDFATLAS9e-final-web.pdf
  • Dwyer-Lindgren L, Cork MA, Sligar A, et al. Mapping HIV prevalence in sub-Saharan Africa between 2000 and 2017. Nature. 2019;570(7760):189–193.
  • Murray CJ, Ortblad KF, Guinovart C, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2014;384(9947):1005–1070.
  • Hamid S, Groot W, Pavlova M. Trends in cardiovascular diseases and associated risks in sub-Saharan Africa: a review of the evidence for Ghana, Nigeria, South Africa, Sudan and Tanzania. Aging Male. 2019;22(3):169–176.
  • Salvi S, Kumar GA, Dhaliwal RS. The burden of chronic respiratory diseases and their heterogeneity across the states of India: the global burden of disease study 1990–2016. Lancet Glob Health. 2018;6(12):e1363–e74.
  • WHO. Global health observatory (GHO) data. Mortality and global health estimates. 2016 [cited 2019 Oct 11]. Available from: http://who.int/gho/mortality_burden_disease/en/
  • Cameron A, Ewen M, Ross-Degnan D, et al. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2009;373(9659):240–249.
  • Aregbeshola BS, Khan SM. Out-of-pocket payments, catastrophic health expenditure and poverty among households in Nigeria 2010. Int J Health Policy Manag. 2018;7(9):798–806.
  • Russo G, Bloom G, McCoy D. Universal health coverage, economic slowdown and system resilience: Africa’s policy dilemma. BMJ Glob Health. 2017;2(3):e000400–e.
  • Hogan DR, Stevens GA, Hosseinpoor AR, et al. Monitoring universal health coverage within the sustainable development goals: development and baseline data for an index of essential health services. Lancet Glob Health. 2018;6(2):e152–e68.
  • Ranabhat CL, Kim CB, Park MB, et al. Multiple disparities in adult mortality in relation to social and health care perspective: results from different data sources. Global Health. 2017;13(1):57.
  • Morton S, Pencheon D, Squires N. Sustainable development goals (SDGs), and their implementation: a national global framework for health, development and equity needs a systems approach at every level. Br Med Bull. 2017;124(1):81–90.
  • Brimble M, Tay D, Seabrook R, et al. Cardiovascular polypill - current and evolving landscape for primary and secondary prevention. 2016 [cited 2019 Oct 10]. Available from https://wellcome.ac.uk/sites/default/files/cardiovascular-polypill-feb17.pdf
  • Haque M, McKimm J, Godman B, et al. Initiatives to reduce postoperative surgical site infections of the head and neck cancer surgery with a special emphasis on developing countries. Expert Rev Anticancer Ther. 2019;19(1):81–92.
  • Godman B, Wettermark B, van Woerkom M, et al. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. Front Pharmacol. 2014;5:106.
  • Godman B, Malmstrom RE, Diogene E, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev Clin Pharmacol. 2015;8(1):77–94.
  • Godman B, Bucsics A, Vella Bonanno P, et al. Barriers for access to new medicines: searching for the balance between rising costs and limited budgets. Front Public Health. 2018;6:328.
  • Godman B, Malmstrom RE, Diogene E, et al. Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs. Front Pharmacol. 2014;5:109.
  • Ermisch M, Bucsics A, Vella Bonanno P, et al. Payers’ views of the changes arising through the possible adoption of adaptive pathways. Front Pharmacol. 2016;7:305.
  • Campbell SM, Godman B, Diogene E, et al. Quality indicators as a tool in improving the introduction of new medicines. Basic Clin Pharmacol Toxicol. 2015;116(2):146–157.
  • Godman B, Shrank W, Andersen M, et al. Policies to enhance prescribing efficiency in europe: findings and future implications. Front Pharmacol. 2010;1:141.
  • Moorkens E, Vulto AG, Huys I, et al. Policies for biosimilar uptake in Europe: an overview. PloS One. 2017;12(12):e0190147.
  • Bochenek T, Abilova V, Alkan A, et al. Systemic measures and legislative and organizational frameworks aimed at preventing or mitigating drug shortages in 28 European and Western Asian countries. Front Pharmacol. 2017;8:942.
  • Godman B, Grobler C, Van-De-Lisle M, et al. Pharmacotherapeutic interventions for bipolar disorder type II: addressing multiple symptoms and approaches with a particular emphasis on strategies in lower and middle-income countries. Expert Opin Pharmacother. 2019;20(18):2237–2255.
  • Godman B, Haque M, McKimm J, et al. Ongoing strategies to improve the management of upper respiratory tract infections and reduce inappropriate antibiotic use particularly among lower and middle-income countries: findings and implications for the future. Curr Med Res Opin. 2020;36(2):301–327.
  • Godman B, Basu D, Pillay Y, et al. Review of ongoing activities and challenges to improve the care of patients with Type 2 diabetes across Africa and the implications for the future. In Press Front Pharmacol. 2020. DOI: 10.3389/fphar.2020.00108
  • World Bank. World bank country and lending groups - country classifications. 2018 [cited 2019 Oct 12]. Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups.
  • OECD/EU. Health at a glance: Europe 2018: state of health in the EU cycle. Paris: OECD Publishing; 2018 [cited 2019 Oct 12]. Available from: https://www.oecd-ilibrary.org/docserver/health_glance_eur-2018-en.pdf?expires=1548072191&id=id&accname=guest&checksum=C37CC57793822050370C2BC1A2CEA2CF
  • Phelan M, Cook C. A treatment revolution for those who can afford it? Hepatitis C treatment: new medications, profits and patients. BMC Infect Dis. 2014;14(Suppl 6):S5.
  • Henry B. Drug pricing & challenges to hepatitis C treatment access. J Health Biomed Law. 2018;14:265–283.
  • Iyengar S, Tay-Teo K, Vogler S, et al. Prices, costs, and affordability of new medicines for hepatitis c in 30 countries: an economic analysis. PLoS Med. 2016;13(5):e1002032–e.
  • Kamal-Yanni M. Hepatitis C drug affordability. Lancet Glob Health. 2015;3(2):e73–4.
  • Aggarwal R, Chen Q, Goel A, et al. Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India. PloS One. 2017;12(5):e0176503.
  • Saez C. WHO - more hepatitis C patients being treated in developing countries; price still an issue. 2016 [cited 2019 Oct 11]. Available from: https://www.ip-watch.org/2016/10/27/hepatitis-c-patients-treated-developing-countries-price-still-issue/
  • Andrieux-Meyer I, Cohn J, de Araujo ES, et al. Disparity in market prices for hepatitis C virus direct-acting drugs. Lancet Glob Health. 2015;3(11):e676–7.
  • Pande S. Steroid containing fixed drug combinations banned by government of India: a big step towards dermatologic drug safety. Indian J Drugs Dermatol. 2016;2:1–2.
  • World Health Organization. Model list of essential medicines. 21st list 2019 [cited 2019 Oct 11]. Available from: https://apps.who.int/iris/bitstream/handle/10665/325771/WHO-MVP-EMP-IAU-2019.06-eng.pdf?ua=1
  • Budd E, Cramp E, Sharland M, et al. Adaptation of the WHO essential medicines list for national antibiotic stewardship policy in England: being AWaRe. J Antimicrob Chemother. 2019;74(11):3384–3389.
  • Hsia Y, Sharland M, Jackson C, et al. Consumption of oral antibiotic formulations for young children according to the WHO access, watch, reserve (AWaRe) antibiotic groups: an analysis of sales data from 70 middle-income and high-income countries. Lancet Infect Dis. 2019;19(1):67–75.
  • Sharland M, Pulcini C, Harbarth S, et al. Classifying antibiotics in the WHO essential medicines list for optimal use-be AWaRe. Lancet Infect Dis. 2018;18(1):18–20.
  • Thera MA, Sehdev PS, Coulibaly D, et al. Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease. J Infect Dis. 2005;192(10):1823–1829.
  • Hobbs CV, Anderson C, Neal J, et al. Trimethoprim-sulfamethoxazole prophylaxis during live malaria sporozoite immunization induces long-lived, homologous, and heterologous protective immunity against sporozoite challenge. J Infect Dis. 2017;215(1):122–130.
  • Manyando C, Njunju EM, D’Alessandro U, et al. Safety and efficacy of co-trimoxazole for treatment and prevention of Plasmodium falciparum malaria: a systematic review. PloS One. 2013;8(2):e56916.
  • Wirtz VJ, Hogerzeil HV, Gray AL, et al. Essential medicines for universal health coverage. Lancet. 2017;389(10067):403–476.
  • World Health Organisation. The selection and use of essential medicines: report of the WHO Expert Committee. 2015 [cited 2019 Oct 10]. Available from: http://apps.who.int/medicinedocs/documents/s22190en/s22190en.pdf
  • Mensah GA, Roth GA, Sampson UK, et al. Mortality from cardiovascular diseases in sub-Saharan Africa, 1990–2013: a systematic analysis of data from the global burden of disease study 2013. Cardiovasc J Afr. 2015;26(2 Suppl 1):S6–10.
  • Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1–25.
  • Zuhlke L Why heart disease is on the rise in South Africa. 2016 [cited 2019 Oct 11]. Available from: http://theconversation.com/why-heart-disease-is-on-the-rise-in-south-africa-66167
  • Vally M, Irhuma MOE. Primary prevention of coronary artery disease. S Afr Family Pract. 2018;60(2):32–37.
  • Keetile M, Navaneetham K, Letamo G. Patterns and determinants of hypertension in Botswana. Z Gesundh Wiss. 2015;23(5):311–318.
  • Keates AK, Mocumbi AO, Ntsekhe M, et al. Cardiovascular disease in Africa: epidemiological profile and challenges. Nat Rev Cardiol. 2017;14(5):273–293.
  • Ministry of Health Kenya. Kenya national guidelines for cardiovascular diseases management - division of non-communicable diseases ministry of health. 2018 [cited 2019 Oct 12]. Available from: http://www.health.go.ke/wp-content/uploads/2018/06/Cardiovascular-guidelines-2018_A4_Final.pdf
  • Maduagu ATL, Oguntona CRB, Oguntona EB, et al. Prevalence of coronary heart diseases risk factors in adults population living in nigeria’s largest urban city. J Nutr Disord Ther. 2015;5:153.
  • Ofori-Asenso R, Garcia D. Cardiovascular diseases in Ghana within the context of globalization. Cardiovasc Diagn Ther. 2016;6(1):67–77.
  • Xie L, Frech-Tamas F, Marrett E, et al. A medication adherence and persistence comparison of hypertensive patients treated with single-, double- and triple-pill combination therapy. Curr Med Res Opin. 2014;30(12):2415–2422.
  • Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;125(9):882–7.e1.
  • Barrios V, Escobar C, Echarri R. Fixed combinations in the management of hypertension: perspectives on lercanidipine-enalapril. Vasc Health Risk Manag. 2008;4(4):847–853.
  • Vlachopoulos C, Grammatikou V, Kallistratos M, et al. Effectiveness of perindopril/amlodipine fixed dose combination in everyday clinical practice: results from the EMERALD study. Curr Med Res Opin. 2016;32(9):1605–1610.
  • Mancia G, Asmar R, Amodeo C, et al. Comparison of single-pill strategies first line in hypertension: perindopril/amlodipine versus valsartan/amlodipine. J Hypertens. 2015;33(2):401–411.
  • Benjamin IJ, Kreutz R, Olsen MH, et al. Fixed-dose combination antihypertensive medications. Lancet. 2019;394(10199):637–638.
  • Putignano D, Orlando V, Monetti VM, et al. Fixed versus free combinations of antihypertensive drugs: analyses of real-world data of persistence with therapy in Italy. Patient Prefer Adherence. 2019;13:1961–1969.
  • Huo Y, Gu Y, Ma G, et al. China STudy of valsartan/amlodipine fixed-dose combination-bAsed long-Term blood pressUre management in HypertenSive patients: a one-year registry (China STATUS III). Curr Med Res Opin. 2019;35(8):1441–1449.
  • Ghiadoni L. Management of high blood pressure in type 2 diabetes: perindopril/indapamide fixed-dose combination and the ADVANCE trial [corrected]. Expert Opin Pharmacother. 2010;11(10):1647–1657.
  • Du L-P, Cheng Z-W, Zhang Y-X, et al. The impact of fixed-dose combination versus free-equivalent combination therapies on adherence for hypertension: a meta-analysis. J Clin Hypertens (Greenwich, CT). 2018;20(5):902–907.
  • Ihm SH, Shin J, Park CG, et al. Efficacy of a fixed dose combination of irbesartan and atorvastatin (Rovelito((R))) in Korean adults with hypertension and hypercholesterolemia. Drug Des Devel Ther. 2019;13:633–645.
  • Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104.
  • Wan X, Ma P, Zhang X. A promising choice in hypertension treatment: fixed-dose combinations. Asian J Pharm. 2014;9(1):1–7.
  • Weir MR, Hsueh WA, Nesbitt SD, et al. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide. J Clin Hypertens. 2011;13(6):404–412.
  • Vedanthan R, Bernabe-Ortiz A, Herasme OI, et al. Innovative approaches to hypertension control in low- and middle-income countries. Cardiol Clin. 2017;35(1):99–115.
  • Nashilongo MM, Singu B, Kalemeera F, et al. Assessing adherence to antihypertensive therapy in primary health care in namibia: findings and implications. Cardiovasc Drugs Ther. 2017;31(5–6):565–578.
  • Nielsen JO, Shrestha AD, Neupane D, et al. Non-adherence to anti-hypertensive medication in low- and middle-income countries: a systematic review and meta-analysis of 92443 subjects. J Hum Hypertens. 2017;31(1):14–21.
  • Awad A, Osman N, Altayib S. Medication adherence among cardiac patients in Khartoum State, Sudan: a cross-sectional study. Cardiovasc J Afr. 2017;28(6):350–355.
  • Godman B, Acurcio F, Guerra Junior AA, et al. Initiatives among authorities to improve the quality and efficiency of prescribing and the implications. J Pharm Care Health Syst. 2014;1(3):1–15.
  • Rampamba EM, Meyer JC, Godman B, et al. Evaluation of antihypertensive adherence and its determinants at primary healthcare facilities in rural South Africa. J Comp Eff Res. 2018;7(7):661–672.
  • Rampamba EM, Meyer JC, Helberg E, et al. Knowledge of hypertension and its management among hypertensive patients on chronic medicines at primary health care public sector facilities in South Africa; findings and implications. Expert Rev Cardiovasc Ther. 2017;15(8):639–647.
  • Fox MP, Pascoe S, Huber AN, et al. Adherence clubs and decentralized medication delivery to support patient retention and sustained viral suppression in care: results from a cluster randomized evaluation of differentiated ART delivery models in South Africa. PLoS Med. 2019;16:7.
  • Kalungia CA, Mwale M, Sondashi IS, et al. Availability of essential antihypertensive and antidiabetic medicines in public health facilities in Lusaka district, Zambia. Med J Zambia. 2017;44(3):140–148.
  • Mitkova ZE, Tachkov K, Petrova G, et al. Factors influencing generics and fixed dose combinations recommendation by pharmacists for cardiology patients. AJPP. 2015;9(43):1020–1025.
  • Petrova G, Doneva M, Mitkova Z, et al. Generics and fixed-dose combinations in cardiology: satisfaction analysis of pharmacists and cardiologists. Biotechnol Biotechnol Equip. 2016;30(1):204–211.
  • Hennekens C. Fixed-dose combination therapy with statins: strengths, limitations and clinical and regulatory considerations. Am J Cardiovasc Drugs. 2008;8(3):155–160.
  • Sica D. Rationale for fixed-dose combinations in the treatment for hypertension. Drugs. 2002;62(3):443–462.
  • Redon J, Pichler G. Comparative study of the efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabetes. J Hypertens. 2016;34(2):359–367.
  • Taddei S. Fixed-dose combination therapy in hypertension: pros. High Blood Press Cardiovasc Prev. 2012;19(2):55–57.
  • Volpe M, Tocci G, de la Sierra A, et al. Personalised single-pill combination therapy in hypertensive patients: an update of a practical treatment platform. High Blood Press Cardiovasc Prev. 2017;24(4):463–472.
  • Gorostidi M. de la Sierra A. Combination therapies for hypertension - why we need to look beyond RAS blockers. Expert Rev Clin Pharmacol. 2018;11(9):841–853.
  • Mbui JM, Oluka MN, Guantai EM, et al. Prescription patterns and adequacy of blood pressure control among adult hypertensive patients in Kenya; findings and implications. Expert Rev Clin Pharmacol. 2017;10(11):1263–1271.
  • James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (JNC 8). Jama. 2014;311(5):507–520.
  • Mwita JC, Francis JM, Omech B, et al. Glycaemic, blood pressure and low-density lipoprotein-cholesterol control among patients with diabetes mellitus in a specialised clinic in Botswana: a cross-sectional study. BMJ Open. 2019;9(7):e026807.
  • Simons LA, Chung E, Ortiz M. Long-term persistence with single-pill, fixed-dose combination therapy versus two pills of amlodipine and perindopril for hypertension: Australian experience. Curr Med Res Opin. 2017;33(10):1783–1787.
  • Gadzhanova S, Roughead EE, Bartlett LE. Long-term persistence to mono and combination therapies with angiotensin converting enzymes and angiotensin II receptor blockers in Australia. Eur J Clin Pharmacol. 2016;72(6):765–771.
  • Weir MR. The rationale for combination versus single-entity therapy in hypertension. Am J Hypertens. 1998;11(10):163s–9s.
  • Berry KM, Parker WA, Mchiza ZJ, et al. Quantifying unmet need for hypertension care in South Africa through a care cascade: evidence from the SANHANES, 2011‐2012. BMJ Glob Health. 2017;2(3):e000348.
  • Cappuccio FP, Miller MA. Cardiovascular disease and hypertension in sub-Saharan Africa: burden, risk and interventions. Intern Emerg Med. 2016;11(3):299–305.
  • Sherrill B, Halpern M, Khan S, et al. Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens. 2011;13(12):898–909.
  • Stankus V, Hemmelgarn B, Campbell NR, et al. Reducing costs and improving hypertension management. Can J Clin Pharmacol. 2009;16(1):e151–5.
  • Akazawa M, Fukuoka K. Economic impact of switching to fixed-dose combination therapy for Japanese hypertensive patients: a retrospective cost analysis. BMC Health Serv Res. 2013;13:124.
  • Dickson M, Plauschinat CA. Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Am J Cardiovasc Drugs. 2008;8(1):45–50.
  • Tung YC, Lin YS, Wu LS, et al. Clinical outcomes and healthcare costs in hypertensive patients treated with a fixed-dose combination of amlodipine/valsartan. J Clin Hypertens. 2015;17(1):51–58.
  • Costa FV. Improving adherence to treatment and reducing economic costs of hypertension: the role of olmesartan-based treatment. High Blood Press Cardiovasc Prev. 2017;24(3):265–274.
  • Ferrario CM, Panjabi S, Buzinec P, et al. Clinical and economic outcomes associated with amlodipine/renin-angiotensin system blocker combinations. Ther Adv Cardiovasc Dis. 2013;7(1):27–39.
  • Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559.
  • Dalal K, Ganguly B, Gor A. Assessment of rationality of fixed dose combinations approved in CDSCO List. J Clin Diagn Res. 2016;10(4):Fc05–8.
  • Lloyd-Sherlock P, Beard J, Minicuci N, et al. Hypertension among older adults in low- and middle-income countries: prevalence, awareness and control. Int J Epidemiol. 2014;43(1):116–128.
  • Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta‐analysis. Lancet. 2016;387(10022):957‐967.
  • Kishore SP, Salam A, Rodgers A, et al. Fixed-dose combinations for hypertension. Lancet. 2018;392(10150):819–820.
  • Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Soci Hypertens. 2018;12(8):579.e1-.e73.
  • Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). J Hypertens. 2013;31(7):1281–1357.
  • Bashir S, Sherwani MU, Shabbir I, et al. Efficacy of fix dose combination (atorvastatin and amlodipine) in treatment of uncontrolled hypertension and dyslipidemia. J Ayub Medical College Abbottabad. 2011;23(3):97–100.
  • Schaffer AL, Buckley NA, Pearson SA. Who benefits from fixed-dose combinations? Two-year statin adherence trajectories in initiators of combined amlodipine/atorvastatin therapy. Pharmacoepidemiol Drug Saf. 2017;26(12):1465–1473.
  • Sharrock T The cost-effectiveness of fixed-dose combinations for preventive cardiovascular pharmacotherapy. 2018 [cited 2019 Oct 10]. Available from: https://ourarchive.otago.ac.nz/bitstream/handle/10523/8471/SharrockTal2018MPH.pdf?sequence=3&isAllowed=y
  • Bartlett LE, Pratt N, Roughead EE. Does a fixed-dose combination of amlodipine and atorvastatin improve persistence with therapy in the Australian population? Curr Med Res Opin. 2018;34(2):305–311.
  • Ma YB, Chan P, Zhang Y, et al. Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia. Expert Opin Pharmacother. 2019;20(8):917–928.
  • Zhu Y, Hu H, Yang J, et al. The efficacy and safety of statin in combination with ezetimibe compared with double-dose statin in patients with high cardiovascular risk: a meta-analysis. Bosn J Basic Med Sci. 2019.
  • Schlackow I, Kent S, Herrington W, et al. Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney Int. 2019;96(1):170–179.
  • Mazza A, Torin G, D’Amicis C, et al. Cost-effectiveness of rosuvastatin/ezetimibe therapy in high-risk hypertensive patients with uncontrolled hypercholesterolemia by a previous simvastatin/ezetimibe treatment. J Hypertens. 2019;37(e–Supplement 1):e228.
  • Bartlett LE, Pratt N, Roughead EE. Does tablet formulation alone improve adherence and persistence: a comparison of ezetimibe fixed dose combination versus ezetimibe separate pill combination? Br J Clin Pharmacol. 2017;83(1):202–210.
  • Pappa E, Rizos CV, Filippatos TD, et al. Emerging fixed-dose combination treatments for hyperlipidemia. J Cardiovasc Pharmacol Ther. 2019;24(4):315–322.
  • Godman B, Schwabe U, Selke G, et al. Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid-lowering drugs. PharmacoEconomics. 2009;27(5):435–438.
  • Leporowski A, Godman B, Kurdi A, et al. Ongoing activities to optimize the quality and efficiency of lipid-lowering agents in the Scottish national health service: influence and implications. Expert Rev Pharmacoecon Outcomes Res. 2018;18(6):655–666.
  • Bae JC, Min KW, Kim YH, et al. Efficacy and safety of fixed-dose combination therapy with gemigliptin (50 mg) and rosuvastatin compared with monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): a multicentre, randomized, double-blind, controlled, phase 3 trial. Diabetes Obes Metab. 2019;21(1):103–111.
  • Mogielnicki M, Swieczkowski D, Bachorski W, et al. The food and drug administration (FDA) and the European medicines agency (EMA) perspective on cardiovascular polypill: a multidimensional concept. Cardiol J. 2016;23(5):515–517.
  • Lopez-Jaramillo P, Gonzalez-Gomez S, Zarate-Bernal D, et al. Polypill: an affordable strategy for cardiovascular disease prevention in low-medium-income countries. Ther Adv Cardiovasc Dis. 2018;12(6):169–174.
  • Barrios V, Kaskens L, Castellano JM, et al. Usefulness of a cardiovascular polypill in the treatment of secondary prevention patients in spain: a cost-effectiveness study. Rev Esp Cardiologia. 2017;70(1):42–49.
  • Gaziano TA, Pandya A, Sy S, et al. Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States. Am Heart J. 2019;214:77–87.
  • Nansseu JR, Tankeu AT, Kamtchum-Tatuene J, et al. Fixed-dose combination therapy to reduce the growing burden of cardiovascular disease in low- and middle-income countries: feasibility and challenges. J Clin Hypertens. 2018;20(1):168–173.
  • Huffman MD, Xavier D, Perel P. Uses of polypills for cardiovascular disease and evidence to date. Lancet. 2017;389(10073):1055–1065.
  • Webster R, Bullen C, Patel A, et al. Impact of switching to polypill based therapy by baseline potency of medication: post-hoc analysis of the SPACE Collaboration dataset. Int J Cardiol. 2017;249:443–447.
  • Roshandel G, Khoshnia M, Poustchi H, et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet. 2019;394(10199):672–683.
  • Franczyk B, Gluba-Brzozka A, Jurkiewicz L, et al. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy? Expert Opin Pharmacother. 2018;19(17):1857–1865.
  • Kolte D, Aronow WS, Banach M. Polypills for the prevention of cardiovascular diseases. Expert Opin Investig Drugs. 2016;25(11):1255–1264.
  • Moriarty F, Bennett K, Fahey T. Fixed-dose combination antihypertensives and risk of medication errors. Heart. 2019;105(3):204–209.
  • Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017;389(10085):2239–2251.
  • American Diabetes Association. (7) Approaches to glycemic treatment. Diabetes Care. 2015;38(Suppl):S41–8.
  • Driver C, Bamitale KDS, Kazi A, et al. Cardioprotective effects of metformin. J Cardiovasc Pharmacol. 2018;72(2):121–127.
  • Montvida O, Shaw J, Atherton JJ, et al. Long-term trends in antidiabetes drug usage in the U.S.: real-world evidence in patients newly diagnosed with type 2 diabetes. Diabetes Care. 2018;41(1):69–78.
  • Jain RK. Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus. Expert Opin Pharmacother. 2017;18(6):545–549.
  • Blonde L, San Juan ZT. Fixed-dose combinations for treatment of type 2 diabetes mellitus. Adv Ther. 2012;29(1):1–13.
  • Bajaj HS, Ye C, Jain E, et al. Glycemic Improvement with a fixed-dose combination of DPP-4 inhibitor + metformin in patients with type 2 diabetes (GIFT study). Diabetes Obes Metab. 2018;20(1):195–199.
  • Bluher M, Kurz I, Dannenmaier S, et al. Pill burden in patients with type 2 diabetes in germany: subanalysis from the prospective, noninterventional PROVIL study. Clin Diabetes. 2015;33(2):55–61.
  • Musenge EM, Manankov A, Mudenda B, et al. Glycaemic control in diabetic patients in Zambia. Pan Afr Med J. 2014;19:354.
  • Rwegerera GM, Masaka A, Pina-Rivera Y, et al. Determinants of glycemic control among diabetes mellitus patients in a tertiary clinic in Gaborone, Botswana: findings and implications. Hosp Pract. 2019;47(1):34–41.
  • Stephani V, Opoku D, Beran D. Self-management of diabetes in Sub-Saharan Africa: a systematic review. BMC Public Health. 2018;18(1):1148.
  • Badi S, Abdalla A, Altayeb L, et al. Adherence to antidiabetic medications among sudanese individuals with type 2 diabetes mellitus: a cross-sectional survey. J Patient Exp. 2019;1–6.
  • Blonde L, Dipp S, Cadena D. Combination glucose-lowering therapy plans in T2DM: case-based considerations. Adv Ther. 2018;35(7):939–965.
  • Wang J-S, Huang C-N, Hung Y-J, et al. Acarbose plus metformin fixed-dose combination outperforms acarbose monotherapy for type 2 diabetes. Diabetes Res Clin Pract. 2013;102(1):16–24.
  • González-Ortiz M, Guerrero-Romero JF, Violante-Ortiz R, et al. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus. J Diabetes Complications. 2009;23(6):376–379.
  • Garnock-Jones KP. Saxagliptin/Dapagliflozin: a review in type 2 diabetes mellitus. Drugs. 2017;77(3):319–330.
  • Davidson JA, Sloan L. Fixed-dose combination of canagliflozin and metformin for the treatment of type 2 diabetes: an overview. Adv Ther. 2017;34(1):41–59.
  • Hu J, Zou P, Zhang S, et al. Empagliflozin/metformin fixed-dose combination: a review in patients with type 2 diabetes. Expert Opin Pharmacother. 2016;17(18):2471–2477.
  • Harris SB. The power of two: an update on fixed-dose combinations for type 2 diabetes. Expert Rev Clin Pharmacol. 2016;9(11):1453–1462.
  • Vijayakumar TM, Jayram J, Meghana Cheekireddy V, et al. Safety, efficacy, and bioavailability of fixed-dose combinations in type 2 diabetes mellitus: a systematic updated review. Curr Ther Res Clin Exp. 2017;84:4–9.
  • Lokhandwala T, Smith N, Sternhufvud C, et al. A retrospective study of persistence, adherence, and health economic outcomes of fixed-dose combination vs. loose-dose combination of oral anti-diabetes drugs. J Med Econ. 2016;19(3):203–212.
  • Cersosimo E, Johnson EL, Chovanes C, et al. Initiating therapy in patients newly diagnosed with type 2 diabetes: combination therapy vs a stepwise approach. Diabetes Obes Metab. 2018;20(3):497–507.
  • Loymans RJ, Gemperli A, Cohen J, et al. Comparative effectiveness of long term drug treatment strategies to prevent asthma exacerbations: network meta-analysis. BMJ. 2014;348:g3009.
  • Papi A, Brightling C, Pedersen SE, et al. Asthma. Lancet. 2018;391(10122):783–800.
  • Papi, A, Canonica, GW, Maestrelli, P, & Paggiaro, P. et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med. 2007;356(20):2040‐52.
  • Reddel, HK, FitzGerald, JM, Bateman, ED, Bacharier, LB, Becker, A, & Brusselle, G. (2019). 2019: a fundamental change in asthma management: treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. The European Respiratory Journal, 53(6), 1901046.
  • Tohda Y, Nishima S, Arakawa I, et al. [Cost-effectiveness of salmeterol/fluticasone combination therapy vs. fluticasone propionate in Japanese asthmatic patients]. Yakugaku Zasshi. 2010;130(4):593–603.
  • Beasley R, Fingleton J, Weatherall M. Restriction of LABA use to combination ICS/LABA inhaler therapy in asthma. Thorax. 2013;68(2):119–120.
  • Nelson HS, Weiss ST, Bleecker ER, et al. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129(1):15–26.
  • Doull I, Price D, Thomas M, et al. Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma. Curr Med Res Opin. 2007;23(5):1147–1159.
  • Ismaila AS, Risebrough N, Li C, et al. COST-effectiveness of salmeterol/fluticasone propionate combination (Advair((R))) in uncontrolled asthma in Canada. Respir Med. 2014;108(9):1292–1302.
  • Jonsson B, Berggren F, Svensson K, et al. An economic evaluation of combination treatment with budesonide and formoterol in patients with mild-to-moderate persistent asthma. Respir Med. 2004;98(11):1146–1154.
  • Dalal AA, St Charles M, Petersen HV, et al. Cost-effectiveness of combination fluticasone propionate-salmeterol 250/50 microg versus salmeterol in severe COPD patients. Int J Chron Obstruct Pulmon Dis. 2010;5:179–187.
  • Tee A, Chow WL, Burke C, et al. Cost-effectiveness of indacaterol/glycopyrronium in comparison with salmeterol/fluticasone combination for patients with moderate-to-severe chronic obstructive pulmonary disease: a LANTERN population analysis from Singapore. Singapore Med J. 2018;59(7):383–389.
  • Bjermer L, van Boven JFM, Costa-Scharplatz M, et al. Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population. Respir Res. 2017;18(1):206.
  • Reza Maleki-Yazdi M, Molimard M, Keininger DL, et al. Cost effectiveness of the long-acting beta2-adrenergic agonist (LABA)/long-acting muscarinic antagonist dual bronchodilator indacaterol/glycopyrronium versus the LABA/inhaled corticosteroid combination salmeterol/fluticasone in patients with chronic obstructive pulmonary disease: analyses conducted for Canada, France, Italy, and Portugal. Appl Health Econ Health Policy. 2016;14(5):579–594.
  • Altaf M, Zubedi AM, Nazneen F, et al. Cost-effectiveness analysis of three different combinations of inhalers for severe and very severe chronic obstructive pulmonary disease patients at a tertiary care teaching hospital of South India. Perspect Clin Res. 2015;6(3):150–158.
  • Nannini L, Cates CJ, Lasserson TJ, et al. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2007(4):Cd003794.
  • Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789.
  • National Institute For Health And Care Excellence. Guideline Chronic obstructive pulmonary disease in over 16s: diagnosis and management. 2018 [cited 2019 Oct 20]. Available from: https://www.nice.org.uk/guidance/ng115/resources/chronic-obstructive-pulmonary-disease-in-over-16s-diagnosis-and-management-pdf-66141600098245.
  • GOLD. Teaching slide set. 2018 [cited 2019 Oct 12]. Available from: https://goldcopd.org/gold-teaching-slide-set/
  • Stancheva B, Pencheva V, Petrova D, et al. Inhaled corticosteroids in stable COPD – international recommendations and reality in Bulgaria. Eur Respir J. 2017;50:PA677.
  • Price D, Small I, Haughney J, et al. Comparative cost-effectiveness of therapy change from fluticasone/salmeterol to beclometasone dipropionate/formoterol (Fostair 100/6®). Primary Care Respir J. 2013;22. Abstract 29 [cited 2019 Oct 12]. Available at URL. : https://www.nature.com/articles/pcrj2013105#Sec29
  • van Boven JF, Kocks JW, Postma MJ. Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands. Int J Chron Obstruct Pulmon Dis. 2016;11:2191–2201.
  • Dale PR, Cernecka H, Schmidt M, et al. The pharmacological rationale for combining muscarinic receptor antagonists and beta-adrenoceptor agonists in the treatment of airway and bladder disease. Curr Opin Pharmacol. 2014;16:31–42.
  • Ichinose M, Minakata Y, Motegi T, et al. Study design of VESUTO((R)): efficacy of tiotropium/olodaterol on lung hyperinflation, exercise capacity, and physical activity in Japanese patients with chronic obstructive pulmonary disease. Adv Ther. 2017;34(7):1622–1635.
  • ZuWallack R, Allen L, Hernandez G, et al. Efficacy and safety of combining olodaterol Respimat((R)) and tiotropium HandiHaler((R)) in patients with COPD: results of two randomized, double-blind, active-controlled studies. Int J Chron Obstruct Pulmon Dis. 2014;9:1133–1144.
  • Miravitlles M, Urrutia G, Mathioudakis AG, et al. Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis. Respir Res. 2017;18(1):196.
  • Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J. 2015;45(4):969–979.
  • Chan MC, Tan EC, Yang MC. Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:1079–1088.
  • Hoogendoorn M, Corro Ramos I, Baldwin M, et al. Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results. Int J Chron Obstruct Pulmon Dis. 2019;14:447–456.
  • Capel M, Mareque M, Alvarez CJ, et al. Cost-effectiveness of fixed-dose combinations therapies for chronic obstructive pulmonary disease treatment. Clin Drug Investig. 2018;38(7):611–620.
  • Abdulsalim S, Unnikrishnan MK, Manu MK, et al. Structured pharmacist-led intervention programme to improve medication adherence in COPD patients: a randomized controlled study. Res Social Administrative Pharm. 2018;14(10):909–914.
  • Abdulsalim S, Unnikrishnan MK, Manu MK, et al. Impact of a clinical pharmacist intervention on medicine costs in patients with chronic obstructive pulmonary disease in India. Pharmacoecon Open. 2019.
  • O’Brien J, Pergolizzi JV Jr, van de Laar M, et al. Fixed-dose combinations at the front line of multimodal pain management: perspective of the nurse-prescriber. Nurs Res Rev. 2013;3:9–22.
  • WHO. Expert committee on drug dependence, tramadol: pre-review report agenda item 5.3. 2017. Available from: http://www.who.int/medicines/access/controlled-substances/PreReview_Tramadol.pdf?ua=1
  • WHO. WHO expert committee on drug dependence, forty first report. 2019 [cited 2019 Oct 15]. Available from: https://apps.who.int/iris/bitstream/handle/10665/325073/9789241210270-eng.pdf?ua=1
  • Fynn A, Helberg E, Godman B, et al. Drug utilization review of tramadol hydrochloride in a regional hospital in South Africa; findings and implications. Hosp Pract (1995). 2020. DOI:10.1080/21548331.2020.1724454
  • Merchante IM, Pergolizzi JV Jr., van de Laar M, et al. Tramadol/paracetamol fixed-dose combination for chronic pain management in family practice: a clinical review. ISRN Family Med. 2013;2013(638469):1–15.
  • Cristancho RA, Vecino AI, Misas JD. Cost/effectiveness evaluation of three fixed combinations of acetaminophen and opioids in the management of acute pain in Colombia. Rev Colomb Anestesiol. 2015;43:87–94 [cited 2019 Oct 10]. Available at URL http://www.scielo.org.co/pdf/rca/v43n1/v43n1a11.pdf
  • Moore RA, Derry S, Simon LS, et al. Nonsteroidal anti-inflammatory drugs, gastroprotection, and benefit-risk. Pain Pract. 2014;14(4):378–395.
  • Department of Health Republic of South Africa. South African adult hospital level essential medicines list chapter 26: pain - nemlc recommendations from the meeting of 26 September 2019 [cited 2019 Oct 20]. Available from: https://docs.mymembership.co.za/docmanager/3c53e82b-24f2-49e1-b997-5a35803be10a/00143867.pdf
  • Olaleye A, Okusanya BO, Oduwole O, et al. A systematic review and meta-analysis of dihydroartemisinin-piperaquine versus sulphadoxine-pyrimethamine for malaria prevention in pregnancy. Int J Obstetrics Gynaecology. 2019;146(1):43–55.
  • Medicines for Malaria Venture - Developing antimalarials to save lives. Eurartesim® (dihydroartemisinin-piperaquine). 2019 [cited 2019 Oct 15]. Available from: https://www.mmv.org/access/products-projects/eurartesim-dihydroartemisinin-piperaquine
  • Baiden R, Oduro A, Halidou T, et al. Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania. Malar J. 2015;14:160.
  • Assi SB, Aba YT, Yavo JC, et al. Safety of a fixed-dose combination of artesunate and amodiaquine for the treatment of uncomplicated plasmodium falciparum malaria in real-life conditions of use in Cote d’Ivoire. Malar J. 2017;16(1):8.
  • Banek K, Webb EL, Smith SJ, et al. Adherence to treatment with artemether-lumefantrine or amodiaquine-artesunate for uncomplicated malaria in children in Sierra Leone: a randomized trial. Malar J. 2018;17(1):222.
  • Itoh M, Negreiros Do Valle S, Farias S, et al. Efficacy of artemether-lumefantrine for uncomplicated plasmodium falciparum malaria in Cruzeiro do Sul, Brazil, 2016. Am J Trop Med Hyg. 2018;98(1):88–94.
  • Ebenebe JC, Ntadom G, Ambe J, et al. Efficacy of artemisinin-based combination treatments of uncomplicated falciparum malaria in under-five-year-old nigerian children ten years following adoption as first-line antimalarials. Am J Trop Med Hyg. 2018;99(3):649–664.
  • Chotsiri P, Zongo I, Milligan P, et al. Optimal dosing of dihydroartemisinin-piperaquine for seasonal malaria chemoprevention in young children. Nat Commun. 2019;10(1):480.
  • Daher A, Pereira D, Lacerda MVG, et al. Efficacy and safety of artemisinin-based combination therapy and chloroquine with concomitant primaquine to treat plasmodium vivax malaria in Brazil: an open label randomized clinical trial. Malar J. 2018;17(1):45.
  • Ferreira MVD, Vieira JLF, Almeida ED, et al. Pharmacokinetics of mefloquine administered with artesunate in patients with uncomplicated falciparum malaria from the Brazilian Amazon basin. Malar J. 2018;17(1):268.
  • Sirima SB, Ogutu B, Lusingu JPA, et al. Comparison of artesunate-mefloquine and artemether-lumefantrine fixed-dose combinations for treatment of uncomplicated plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial. Lancet Infect Dis. 2016;16(10):1123–1133.
  • Ligade VS, Thakar TM, Dengale SJ. Fixed dose combinations of anti-tubercular, antimalarial and antiretroviral medicines on the Indian market: critical analysis of ubiquity, sales and regulatory status. Trop Med Int Health. 2019;24(2):238–246.
  • Ezenduka CC, Falleiros DR, Godman BB. Evaluating the treatment costs for uncomplicated malaria at a public healthcare facility in Nigeria and the implications. Pharmacoecon Open. 2017;1(3):185–194.
  • Mori AT, Norheim OF, Robberstad B. Budget impact analysis of using dihydroartemisinin-piperaquine to treat uncomplicated malaria in children in Tanzania. PharmacoEconomics. 2016;34(3):303–314.
  • Manning J, Lon C, Spring M, et al. Cluster-randomized trial of monthly malaria prophylaxis versus focused screening and treatment: a study protocol to define malaria elimination strategies in Cambodia. Trials. 2018;19(1):558.
  • Nguyen TD, Olliaro P, Dondorp AM, et al. Optimum population-level use of artemisinin combination therapies: a modelling study. Lancet Glob Health. 2015;3(12):e758–66.
  • MSF. Treating drug-sensitive Tb in India: implementation of daily therapy with fixed dose combinations. Policy brief 2015 [cited 2019 Oct 10]. Available from: https://www.msfaccess.org/sites/default/files/MSF_assets/TB/Docs/TB_Briefing_FDC_Daily_regimen_India_eng_2015.pdf
  • WHO. Guidelines for treatment of drug-susceptible tuberculosis and patient care. 2017 [cited 2019 Oct 11]. Available from: https://apps.who.int/iris/bitstream/handle/10665/255052/9789241550000-eng.pdf.
  • Ali AO, Prins MH. Patient non adherence to tuberculosis treatment in Sudan: socio demographic factors influencing non adherence to tuberculosis therapy in Khartoum State. Pan Afr Med J. 2016;25:80.
  • Braga JU, Trajman A. Effectiveness of RHZE-FDC (fixed-dose combination) compared to RH-FDC + Z for tuberculosis treatment in Brazil: a cohort study. BMC Infect Dis. 2015;15(1):81.
  • Albanna AS, Smith BM, Cowan D, et al. Fixed-dose combination antituberculosis therapy: a systematic review and meta-analysis. Eur Respir J. 2013;42(3):721–732.
  • Lima GC, Silva EV, Magalhães P, et al. Efficacy and safety of a four-drug fixed-dose combination regimen versus separate drugs for treatment of pulmonary tuberculosis: a systematic review and meta-analysis. Braz J Microbiol. 2017;48(2):198–207.
  • Zuim R, Menezes A, Trajman A. A experiência brasileira com a implementação do 4:1 dose fixa combinada para o tratamento da tuberculose. J Epidemiologia E Serviços De Saúde. 2014;23:537–540.
  • Maciel EL, Braga JU, Bertolde AI, et al. Reflections upon the article “Evaluation of the impact that the changes in tuberculosis treatment implemented in Brazil in 2009 have had on disease control in the country”Authors’ replyEvaluation of the impact that the changes in tuberculosis treatment implemented in Brazil in 2009 have had on disease control in the countryHow do you know which health care effectiveness research you can trust a guide to study design for the PerplexedSegmented regression analysis of interrupted time series studies in medication use researchConducting interrupted time series analysis for single-and multiple-group comparisonsInterrupted time series regression for the evaluation of public health interventions a tutorialHow to obtain the confidence interval from a P value. J Bras Pneumol. 2018;44(3):249–252.
  • Rabahi MF, Silva Junior J, Conde MB. Evaluation of the impact that the changes in tuberculosis treatment implemented in Brazil in 2009 have had on disease control in the country. J Bras Pneumol. 2017;43(6):437–444.
  • Zuur MA, Akkerman OW, Forsman LD, et al. Fixed-dose combination and therapeutic drug monitoring in tuberculosis: friend or foe? Eur Respir J. 2016;48:1230–1233.
  • Ali MH, Alrasheedy AA, Kibuule D, et al. Assessment of multidrug-resistant tuberculosis (MDR-TB) treatment outcomes in Sudan; findings and implications. Expert Rev Anti Infect Ther. 2019;17(11):927–937.
  • Kibuule D, Verbeeck RK, Nunurai R, et al. Predictors of tuberculosis treatment success under the DOTS program in Namibia. Expert Rev Respir Med. 2018;12(11):979–987.
  • Department of Health South Africa. Adherence guidelines for HIV, TB and NCDs - standard operating procedures. 2016. Available from: https://www.nacosa.org.za/wp-content/uploads/2018/05/SOP-Adherence-counselling-A5-booklet-19-03-2017.pdf
  • National Department of Health South Africa. Standard operating procedures for minimum package of interventions to support linkage to care, adherence and retention in care, adherence guidelines for HIV, TB and NCDs. Pretoria, South Africa, 2016 [cited 2019 Oct 12]. Available from: http://www.differentiatedcare.org/Portals/0/adam/Content/_YiT3_-qmECUkmkpQvZAIA/File/SOP%20A5%20booklet%2020-05-2016.pdf
  • Court R, Chirehwa MT, Wiesner L, et al. Quality assurance of rifampicin-containing fixed-drug combinations in South Africa: dosing implications. Int J Tuberc Lung Dis. 2018;22(5):537–543.
  • Sax PE, Meyers JL, Mugavero M, et al. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PloS One. 2012;7(2):e31591.
  • Davies NECG. Fixed-dose combination for adults accessing antiretroviral therapy. South Afr J HIV Med. 2013;14(1). Available from https://sajhivmed.org.za/index.php/hivmed/article/view/104/168
  • Costa J, Ceccato M, Silveira MR, et al. Effectiveness of antiretroviral therapy in the single-tablet regimen era. Revista de saude publica. 2018;52:87.
  • Clay PG, Yuet WC, Moecklinghoff CH, et al. A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV. AIDS Res Ther. 2018;15(1):17.
  • Cotte L, Ferry T, Pugliese P, et al. Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study. PloS One. 2017;12(2):e0170661–e.
  • Sutton SS, Magagnoli J, Hardin JW. Odds of viral suppression by single-tablet regimens, multiple-tablet regimens, and adherence level in HIV/AIDS patients receiving antiretroviral therapy. Pharmacotherapy. 2017;37(2):204–213.
  • Chen Y, Chen K, Kalichman SC. Barriers to HIV medication adherence as a function of regimen simplification. Ann Behav Med. 2017;51(1):67–78.
  • Tarrier L, Kegg S. Who gets single tablet regimens (STR), and why? J Int AIDS Soc. 2014;17(4 Suppl 3):19777.
  • Aldir I, Horta A, Serrado M. Single-tablet regimens in HIV: does it really make a difference? Curr Med Res Opin. 2014;30(1):89–97.
  • Clay PG, Nag S, Graham CM, et al. Meta-analysis of studies comparing single and multi-tablet fixed dose combination HIV treatment regimens. Medicine (Baltimore). 2015;94(42):e1677.
  • Hirasen K, Evans D, Maskew M, et al. The right combination - treatment outcomes among HIV-positive patients initiating first-line fixed-dose antiretroviral therapy in a public sector HIV clinic in Johannesburg, South Africa. Clin Epidemiol. 2018;10:17–29.
  • Altice F, Evuarherhe O, Shina S, et al. Adherence to HIV treatment regimens: systematic literature review and meta-analysis. Patient Prefer Adherence. 2019;13:475–490.
  • Costa JO, Pearson SA, Acurcio FA, et al. Health-related quality of life among HIV-infected patients initiating treatment in Brazil in the single-tablet regimen era. AIDS Care. 2019;31(5):572–581.
  • Usaid Global Health Supply Chain Program Procurement and Supply Management. The dolutegravir opportunity - managing supply chain risk for the introduction of a new antiretroviral (ARV) medicine. [cited 2019 Oct 12]. Available from: https://www.ghsupplychain.org/sites/default/files/2019-07/20_HIV-AIDS%20TLD%201%20pager.pdf
  • WHO. Dolutegravir (DTG) and the fixed dose combination (FDC) of tenofovir/lamivudine/dolutegravir (TLD). Briefing note - April 30 2018 [cited 2019 Oct 11]. Available from: https://www.who.int/hiv/pub/arv/DTG-TLD-arv_briefing_2018.pdf?ua=1
  • Meireles MV, Pascom ARP, Duarte EC, et al. Comparative effectiveness of first-line antiretroviral therapy: results from a large real-world cohort after the implementation of dolutegravir. AIDS. 2019;33(10):1663–1668.
  • Phillips AN, Cambiano V, Nakagawa F, et al. Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study. Lancet HIV. 2018;5(3):e146–e54.
  • Zheng A, Kumarasamy N, Huang M, et al. The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as first-line treatment of HIV infection in India. J Int AIDS Soc. 2018;21(3):e25085.
  • Dorward J, Lessells R, Drain PK, et al. Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research. Lancet HIV. 2018;5(7):e400–e4.
  • Dooley K, Kaplan R, Mwelase N et al. Safety and efficacy of dolutegravir-based art in TB/HIV coinfected adults at week 24. 25th croi 4–7 March 2018 [cited 2019 Oct 15]. Oral abstract 33. Available from: http://www.croiconference.org/sessions/safety-and-efficacy-dolutegravir-based-art-tbhiv-coinfected-adults-week-24.
  • Hill A, Clayden P, Thorne C, et al. Safety and pharmacokinetics of dolutegravir in HIV-positive pregnant women: a systematic review. J Virus Erad. 2018;4(2):66–71.
  • Zash R, Jacobson D, Mayondi G et al. Dolutegravir/tenofovir/emtricitabine (DTG/TDF/FTC) started in pregnancy is as safe as efavirenz/tenofovir/emtricitabine (EFV/TDF/FTC) in nationwide birth outcomes surveillance in Botswana. IAS 2017 - conference on HIV pathogenesis treatment and prevention. . [cited 2019 Oct 15]. Available from: http://www.natap.org/2017/IAS/IAS_142.htm
  • O’Donnell MR, Padayatchi N, Daftary A, et al. Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection. Lancet HIV. 2019;6(3):e201–e4.
  • Pialoux G, Marcelin AG, Cawston H, et al. Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France. Expert Rev Pharmacoecon Outcomes Res. 2018;18(1):83–91.
  • Girouard MP, Sax PE, Parker RA, et al. The cost-effectiveness and budget impact of 2-drug dolutegravir-lamivudine regimens for the treatment of HIV infection in the United States. Clinl Infect Dis. 2016;62(6):784–791.
  • Beck EJ, Mandalia S, Sangha R, et al. Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004–2008. PloS One. 2012;7(10):e47376–e.
  • Angeletti C, Pezzotti P, Antinori A, et al. Antiretroviral treatment based cost saving interventions may offset expenses for new patients and earlier treatment start. HIV Med. 2014;15:165–174.
  • de Oliveira Costa J Pharmacoepidemiological and pharmacoeconomic analysis of antiretroviral treatment in single tablet regimen from the perspective of the Brazilian national health system. 2019 [cited 2019 Oct 20]. Available from:: https://repositorio.ufmg.br/handle/1843/30142
  • Sweet DE, Altice FL, Cohen CJ, et al. Cost-effectiveness of single- versus generic multiple-tablet regimens for treatment of HIV-1 infection in the United States. PloS One. 2016;11(1):e0147821–e.
  • Harries AD, Lawn SD, Suthar AB, et al. Benefits of combined preventive therapy with co-trimoxazole and isoniazid in adults living with HIV: time to consider a fixed-dose, single tablet coformulation. Lancet Infect Dis. 2015;15(12):1492–1496.
  • Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet. 2006;368(9536):679–686.
  • Balat JD, Gandhi AM, Patel PP, et al. A study of use of fixed dose combinations in Ahmedabad, India. Indian J Pharmacol. 2014;46(5):503–509.
  • Gautam CS, Aditya S. Irrational drug combination: need to Sensitize undergraduates. Ind J Pharmacol. 2006;38:167–170.
  • Medication with reason. [cited 2019 Oct 20]. Available from: https://www.liekysrozumom.sk/
  • Dionisio D, Gass R, McDermott P, et al. What strategies to boost production of affordable fixed-dose anti-retroviral drug combinations for children in the developing world? Curr HIV Res. 2007;5(2):155–187.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.